Drugs / ZM-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06292650 | Feb 2024 → Dec 2027 expected | retinitis pigmentosa | Zhongmou Therapeutics | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07282457 | Jun 2026 → Dec 2029 expected | retinitis pigmentosa | Zhongmou Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZM-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06292650 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Modified Optogenetic Gene Therapy (ZM-02 Injection)” NCT07282457 ↗ |
| Route | Intravitreal | “Single unilateral IVT injection of low-dose ZM-02 in the study eye” NCT07282457 ↗ |